Neuroblastoma Market Size

Neuroblastoma Market size was over USD 3.03 Billion in 2023 and is projected to cross USD 5.37 Billion by the end of 2036, witnessing more than 4.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of neuroblastoma is estimated at USD 3.15 Billion. The growth of the market can be attributed to the increasing incidence of neuroblastoma and the development of new and advanced treatment methods. For instance, neuroblastoma accounts for approximately 8–10% of all cases of childhood cancer. According to statistics, neuroblastoma occurs in 11 to 13 children under the age of 15 per million, and in children 10–14 years of age, the incidence rate rises to 65 per million. Neuroblastoma is a type of cancer that affects the peripheral nervous system, which is made up of nerves that connect the central nervous system to the rest of the body. As this type of cancer becomes more common, the need for diagnosis, treatment, and management of the disease is expected to increase, thereby driving the growth of the neuroblastoma market.

 In addition to these, factors that are believed to fuel the market growth of neuroblastoma include increasing investments in the healthcare sector, the rising number of clinical trials, and the growing awareness about the disease among patients. Furthermore, an increasing success rate for cancer immunotherapy is further projected to enhance market growth. For instance, it has been estimated that 87% of children in the UK who have successfully completed immunotherapy have shown no evidence of disease last two years after completing the treatment. Also, five years after immunotherapy begins, approximately 78% of children in remission remain free of disease. The success rate of immunotherapy has been increasing owing to advancements in cancer research and the development of new drugs, which can help to improve the chances of survival for patients with neuroblastoma.